Apollo launches national program to promote rational use of antibiotics

Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes

Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%

H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY

Merck and the Bill & Melinda Gates Medical Research Institute announce licensing agreement for tuberculosis antibiotic candidates

The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.

Panacea Biotec bags US $127.30 mn for supply of Pentavalent Vaccine

UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

Panacea Biotec received US FDA communication for Baddi facility

The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved

World’s first intra nasal vaccine iNCOVACC from Bharat Biotech receives approval

iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy

Dr. Jitendra Singh announces 75 Amrit Grants for biotech initiatives

75 inter-disciplinary, multi-institutional grants would be supported for high-risk, ambitious research ideas, milestones-driven collaborative research in all domain areas of the biotech sector

Growing investment in biotech startups likely to make CAR-T therapies affordable in India, says GlobalData

GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.

Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222

WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".